One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Researchers at Saint Louis University's School of Medicine say T-cell dysfunction is leading to an increased risk of cancer ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

Tumors find different ways to avoid immune cell detection and proliferate in their environment. Antitumor immune cells will ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

"We learned that the dysfunction in these T cells lies in their inability to kill tumors. Those genes were not being turned ...

CART-007, an anti-CD7 CAR T-cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic ...

Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but ...

Dendritic cells are poised to revolutionize oncology. This type of immune therapy shows effectiveness even in late-stage ...